{"filings":[{"id":96352,"accession_number":"0001493152-26-018590","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tevogen Bio receives Nasdaq deficiency notices for market value requirements","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tevogen on Apr 16, 2026 it fails $50M minimum market value for listed securities (MVLS).","Second notice on Apr 17, 2026 for failing $15M minimum market value of publicly held shares (MVPHS).","Company has 180 days to regain compliance: MVLS by Oct 13, 2026; MVPHS by Oct 14, 2026.","Compliance requires closing at or above threshold for 10 consecutive business days.","Tevogen may consider transferring to Nasdaq Capital Market but provides no assurance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110179,"accession_number":"0001493152-26-012701","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tevogen Bio regains Nasdaq minimum bid price compliance after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 20, 2026 confirming compliance with Listing Rule 5450(a)(1).","Compliance achieved via 1-for-50 reverse stock split of common stock effective March 6, 2026.","Nasdaq matter now closed; no further delisting risk from this requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110178,"accession_number":"0001493152-26-008786","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Tevogen Bio announces 1-for-50 reverse stock split effective March 6, 2026 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1-for-50; effective 12:01 a.m. March 6, 2026.","Pre-split shares outstanding: 202,416,556 as of March 3, 2026.","Directors and executive officers beneficially own >70% of common stock.","No fractional shares issued; cash paid in lieu based on closing price day before effective date.","Authorized shares unchanged at 800M; symbol TVGN remains; new CUSIP 88165K200."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110177,"accession_number":"0001493152-26-008065","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.","Shareholders authorized reverse stock split at ratio between 1:25 and 1:85, with exact ratio set by Board in its discretion.","Both proposals passed with strong support: 147.8M for plan amendment; 176.3M for reverse split (no broker non-votes on split).","182.4 million shares were represented at the special meeting, ~90.5% of outstanding 201.5M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110176,"accession_number":"0001493152-26-004461","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tevogen Bio board to evaluate potential one-time special cash dividend after unspecified milestones","summary_kind":"llm","event_type":"dividend","confidence":"medium","bullets":["Board intends to evaluate a special cash dividend contingent on future financial milestones (revenue, earnings targets).","No dividend has been declared; any declaration subject to financial performance, solvency laws, and board approval.","No assurance can be given on timing, amount, or whether a dividend will occur at all.","Company plans to provide further updates as appropriate under disclosure requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143526,"accession_number":"0001493152-25-015784","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.","Common stock closing bid below $1.00 for 30 consecutive business days; no immediate impact on listing.","Has 180 days (until March 23, 2026) to regain compliance by closing at $1.00+ for at least 10 consecutive days.","If not cured, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","Company will monitor bid price and evaluate options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143525,"accession_number":"0001641172-25-018533","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tevogen Bio grants 8M restricted shares to CEO; total outstanding 193.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved restricted stock awards on June 27, 2025, including 8M shares to CEO Dr. Ryan Saadi.","Total outstanding shares now 193,693,433.","CEO's shares vest in four equal annual installments starting on the seventh anniversary of grant.","Other grantees' shares vest in three equal annual installments starting on the fifth anniversary.","Shares subject to forfeiture if continuous service not maintained; cannot be transferred before vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143524,"accession_number":"0001641172-25-017873","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tevogen Bio enters $50M at-the-market equity sales agreement with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement allows issuance and sale of up to $50M of common stock from time to time.","Sales will be made through A.G.P./Alliance Global Partners as agent at market prices.","Offering conducted under effective shelf registration statement (File No. 333-288218).","Company pays agent a commission on gross proceeds and provides customary indemnification.","Company is not obligated to sell any shares and may terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161717,"accession_number":"0001641172-25-017198","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO Ryan Saadi contributes $500,000 to Tevogen Bio for new HQ costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Founder and CEO Ryan Saadi contributed $500,000 cash to Tevogen Bio on June 30, 2025.","Contribution earmarked for build-out and first-year operating costs of new Warren, NJ headquarters.","CEO personally funding corporate infrastructure expansion, signaling insider commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161716,"accession_number":"0001641172-25-016126","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect Feike and Patton as Class I directors; ratify KPMG as auditor.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey Feike received 150,304,146 votes for and 652,203 against; Dr. Curtis Patton: 150,313,660 for, 647,811 against.","Ratification of KPMG LLP as independent auditor for FY2025: 167,188,556 for, 92,456 against, 79,574 abstentions.","Annual Meeting held June 23, 2025; quorum of 167,360,586 shares (91% of outstanding) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161715,"accession_number":"0001641172-25-013396","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tevogen Bio doubles HQ leased space to 13,242 RSF; lease extended to Feb 2033","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease amendment doubles space from 6,708 to 13,242 rentable square feet on Building's 2nd floor.","Term extended seven years to February 28, 2033; annual base rent approx. $330,000 ($24.75/RSF).","Relocation from 4th floor to 2nd floor effective June 1, 2025; prior lease terminated.","Employees from Philadelphia R&D center to be relocated after its lease expires June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161714,"accession_number":"0001641172-25-006227","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tevogen Bio amends Bylaws to modify director resignation procedure for majority vote failures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended Bylaws on April 21, 2025 to alter process for director resignations when director fails to receive majority vote in uncontested election.","Amendment filed as Exhibit 3.1; no other changes to Bylaws or fiscal year announced.","Procedural governance amendment with no immediate financial or operational impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161713,"accession_number":"0001641172-25-005236","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tevogen Bio inks related-party facility deal with CD8 for cell therapy production","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.","Tevogen to provide primary staff and operations; facility supports both pre-clinical research and GMP production.","Initial term of 12 months, auto-renewing; specific costs, scope, and timelines to be set in future work orders.","Agreement formalizes previously announced letter of intent and aligns with previously stated topline forecasts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179815,"accession_number":"0001493152-25-004002","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tevogen Bio receives $2M grant from KRHP LLC; up to $10M non-dilutive funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $2M grant from KRHP LLC; additional $8M contingent on KRHP's review of activities.","Funding is non-dilutive and will support development of off-the-shelf T cell therapies for cancers and viral infections.","Tevogen may also use grant to expand AI efforts (Tevogen.AI) in partnership with Microsoft.","KRHP LLC is affiliated with spouse of Dr. Manmohan Patel, an existing >5% beneficial owner of TVGN common stock.","Grant is in addition to previously announced $36M loan agreement from Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212879,"accession_number":"0001493152-24-033873","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-08-26T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Tevogen Bio raises $6M via Series C Preferred Stock; two closings Aug 30 & Sept 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor to purchase 600 shares of Series C Preferred Stock for $6.0 million aggregate.","First closing of $4.0M on Aug 30, 2024; second closing of $2.0M on Sept 16, 2024.","Conversion price: VWAP over 30 trading days prior to conversion, floor $0.6172; subject to 9.99% beneficial ownership limit.","Preferred stock carries 7.5% annual cumulative dividend, payable in kind or cash, starting Sept 30, 2024.","Company has call right after five years; stock is non-voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212880,"accession_number":"0001493152-24-033756","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","9.01"],"status":"ready","headline":"Tevogen Bio raises $6M via Series C Preferred; director Suren Ajjarapu resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 600 shares of Series C Preferred at $10,000 each for $6.0M aggregate to The Patel Family, LLP.","Series C carries 7.5% annual cumulative dividend, convertible after 6 months at VWAP floor $0.6172.","Conversion subject to 9.99% beneficial ownership limitation; pre-funded warrants issued if exceeded.","Director Suren Ajjarapu resigned effective August 21, 2024, with no disagreement with the company.","Proceeds from unregistered sale used for general corporate purposes; stock not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231951,"accession_number":"0001493152-24-024727","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","1.02","3.01","9.01"],"status":"ready","headline":"Tevogen Bio receives Nasdaq bid price deficiency notice, repurchases Series B Preferred Stock","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 14, 2024, for non-compliance with $1.00 minimum bid price rule for 35 consecutive business days.","Company has 180 days until December 11, 2024, to regain compliance by closing bid price at $1.00 or more for 10 consecutive days.","Repurchased all 3,613 shares of Series B Preferred Stock from SSVK Associates LLC on June 15, 2024, reassuming $3.6 million liabilities.","Suren Ajjarapu, managing member of SSVK, is a board member; SSVK owns over 5% of common stock.","Repurchase cancelled all outstanding Series B Preferred Stock; related Assignment and Assumption Agreement terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231950,"accession_number":"0001493152-24-023483","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Tevogen Bio secures $36M unsecured credit line from 5% owner Patel Family; equity-linked terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement with The Patel Family LLP (affiliate of 5% holder Manmohan Patel) for up to $36M unsecured facility.","Monthly draws up to $1M; interest is lower of SOFR+2% or 7%, payable quarterly in shares at $1.50/share.","Repayment in cash or stock at greater of $1.50 or 10-day VWAP; maturity 48 months per draw.","Lender gets option to buy $14M+ in stock at 30% discount to VWAP when stock hits $10 (PIPE).","Issuance capped at 19.99% of shares without stockholder consent; 1M commitment shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231945,"accession_number":"0001493152-24-021990","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-05-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Tevogen Bio Inc reports 2023 net loss of $60.5M; cash only $1.05M, going concern raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $60.5M in 2023 ($2.44/share) vs $22.0M in 2022; no revenue.","Operating expenses $8.8M; $50.4M non-cash loss from change in fair value of convertible notes.","Accumulated deficit $99.7M; cash $1.05M at Dec 31, 2023.","Auditors express substantial doubt about ability to continue as going concern.","Post-balance sheet: $2M Series A Preferred (Feb 2024) and $1.2M Series A-1 Preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231949,"accession_number":"0001493152-24-020275","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tevogen Bio enters $36M line of credit with Patel Family; also grants PIPE option for $14M+","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Line of credit up to $36M, draws limited to $1M per month; interest lower of SOFR+2% or 7%.","Interest payable in common shares at $1.50/share; principal due 48 months after draw; prepayment without penalty in cash or stock.","Lender gets option to buy $14M+ in common stock at 30% discount to 10-day VWAP when TVGN hits $10/share.","Commitment fee of 1M shares to be issued upon signing definitive agreement by June 14, 2024.","Patel Family, LLP is an affiliate of 5% holder Manmohan Patel; beneficial ownership limited to 9.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231948,"accession_number":"0001493152-24-017597","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Tevogen Bio Holdings appoints KPMG as auditor, dismisses Marcum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee appointed KPMG as independent auditor for FY2024, effective immediately.","Marcum dismissed as auditor; its prior reports contained a going-concern explanatory paragraph.","Company disclosed a material weakness in internal controls over complex financial instruments and related-party collectability.","No disagreements or reportable events with Marcum; Marcum provided a letter agreeing with disclosures.","KPMG had served as auditor for Tevogen Bio Inc. prior to the June 2023 business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231944,"accession_number":"0001493152-24-016797","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-04-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.","Cash of $1.05M as of Dec 31, 2023; management cites substantial doubt about going concern.","Convertible promissory notes total $94.9M, with $80.7M current; fair value change of $50.4M recorded as loss.","Total operating expenses $8.8M (R&D $4.4M, G&A $4.4M), down from $13.7M in 2022.","Business combination with Semper Paratus closed Feb 14, 2024; post-merger financing included $2M Series A and $1.2M Series A-1 preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231947,"accession_number":"0001493152-24-016060","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tevogen Bio expects to eliminate $94.9M liabilities via note conversion; launches AI initiative, appoints new leaders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.","Pro forma balance sheet shows no remaining convertible note liabilities; $80.7M current and $14.2M long-term removed.","Operating expenses for Tevogen Bio Inc. in 2023 were $8.8M, primarily non-cash charges from note fair value changes.","Launches Tevogen.ai AI initiative to enhance drug discovery, manufacturing, and patient access; Mittul Mehta appointed CIO.","Appoints Tapan V. Shah as Head of Investor Relations and Corporate Development; 25-year Wall Street veteran."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231943,"accession_number":"0001493152-24-014240","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-04-10T23:59:59+00:00","items":["3.02","1.01","5.03","9.01"],"status":"ready","headline":"Tevogen Bio raises $6.0M via Series A-1 Preferred Stock sale to existing investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 600 shares of Series A-1 Preferred at $10,000/share to Patel Family, LLP, affiliated with >5% holder Dr. Manmohan Patel.","Preferred converts into 600,000 common shares; carries 5% cumulative dividend, increasing 2%/yr, max 15%.","Company has call right to redeem at $10,000 plus accrued dividends if 20-day VWAP exceeds $5.00 and registration effective.","Series A-1 Preferred ranks pari passu with Series A Pref and senior to common and Series B on liquidation.","Amendment corrects omission of Item 3.02 disclosure; original filing on March 27, 2024 is restated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231946,"accession_number":"0001493152-24-012650","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Tevogen Bio issues $6M Series A-1 Preferred to existing investor Patel; convertible into 600K common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 600 shares Series A-1 Preferred Stock at $10,000/share for aggregate $6.0M to The Patel Family, LLP.","Preferred carries 5% annual cumulative dividend increasing 2% yearly (capped at 15%); convertible into 600,000 common shares.","Company has call right if 20-day VWAP > $5.00 and resale registration effective; non-voting, no mandatory redemption.","Investment made under Section 4(a)(2) exemption; existing investor Dr. Manmohan Patel is beneficial owner >5%.","Series A-1 ranks pari passu with Series A, senior to Common and Series B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250238,"accession_number":"0001493152-24-010806","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tevogen Bio issues Series A and Series B Preferred Stock to raise $8M and settle ~$3.6M liabilities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Created Series A Preferred Stock sold to Dr. Manmohan Patel for $8M ($4,000 per share), cumulative 5% annual dividend rising 2% yearly.","Series A holders can convert to common stock at any time; company can call at $4,000/share if VWAP >$5.00 for 20 days.","Series B Preferred Stock issued to Sponsor for assuming ~$3.6M in liabilities; quarterly dividend starts at 3.25% per quarter, increasing monthly up to 7.5%.","Series A ranks senior to all common and Series B; Series B ranks junior to Series A but senior to common stock.","Both series have no maturity, no sinking fund, no voting rights (except as required by law or specified)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250237,"accession_number":"0001493152-24-007408","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.05","9.01"],"status":"ready","headline":"Tevogen Bio adopts Code of Business Conduct and Ethics on Feb 14, 2024","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Company adopted a Code of Business Conduct and Ethics effective February 14, 2024.","Code applies to all officers, directors, and employees, including CEO and CFO.","Code filed as Exhibit 14.1 to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250236,"accession_number":"0001493152-24-007138","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","8.01","3.02","9.01"],"status":"ready","headline":"Tevogen Bio raises $8M via Series A Preferred, assumes >$4.2M liabilities via Series B Preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series A Preferred raised $8M in two installments ($2M due Feb 15, $6M by Mar 16); convertible into 2M shares.","Series A carries 5% cumulative dividend (increases 2% annually); callable if 20-day VWAP >$5.00 and S-1 effective.","Series B Preferred issued to SSVK for assuming >$4.2M liabilities; 3.5% quarterly dividend (up to 7.5% quarterly cap).","SSVK converted $1.5M and Mr. Ajjarapu converted $240K loans into common at $10/share; $2M merger obligation reduced to $500K.","Issued 600K shares to two financial institutions for capital markets advisory services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250235,"accession_number":"0001493152-24-006751","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","2.01","5.02","3.02","9.01","3.03","5.03","5.01","5.06"],"status":"ready","headline":"Tevogen Bio completes SPAC merger valued at $1.2B, shares trade under LGST","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CEO Ryan Saadi owns 72.3% of outstanding shares (118.35M of 163.75M) after business combination.","$24.0M in convertible promissory notes assumed and converted into 10,337,419 shares of common stock.","Lock-up restricts transfer of shares by sponsor and CEO for 6 months or $12 price threshold.","Pre-revenue biotech with no approved products; 2023 CEO salary $501K, CFO $300K, CSO $350K.","Adopts 2024 Omnibus Incentive Plan and enters indemnification agreements with directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250234,"accession_number":"0001493152-24-004562","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Semper Paratus shareholders approve merger with Tevogen Bio; redemptions ~$15.9M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders approved all proposals, including business combination, domestication, and charter changes.","Approximately 1.43M public shares redeemed for ~$15.9M (~$11.07 per share) from trust.","Combined company expected to trade on Nasdaq as 'TVGN' after closing.","Elected board: Dr. Curtis Patton, Jeffrey Feike, Surendra Ajjarapu, Victor Sordillo, Dr. Keow Lin Goh, Dr. Ryan Saadi, Susan Podlogar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250233,"accession_number":"0001493152-24-003611","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Semper Paratus shifts combined Tevogen Bio listing target to Nasdaq from NYSE American","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Parties agreed to seek Nasdaq listing for New Tevogen common stock and public warrants instead of NYSE American.","Prospectus Supplement filed on Jan 24, 2024 to revise prior proxy statement/prospectus.","Shareholder meeting to vote on business combination with Tevogen Bio remains scheduled for Jan 29, 2024.","Semper Paratus (LGST, LGSTW) will redomesticate to Delaware and rename to Tevogen Bio Holdings Inc. upon closing.","Tevogen Bio is a clinical-stage immunotherapy company with wholly owned IP including three granted patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250232,"accession_number":"0001493152-24-001170","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SEC declares effective registration statement for Semper Paratus–Tevogen Bio merger; $1.2B equity value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SEC declared effective the Form S-4 for the business combination between Semper Paratus (LGST) and Tevogen Bio.","Pro forma equity value of combined company attributable to Tevogen stockholders expected to be $1.2 billion.","Special meeting of Semper Paratus stockholders to approve the transaction; closing expected shortly after subject to approvals.","Post-closing combined company will be renamed Tevogen Bio Holdings Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267773,"accession_number":"0001493152-23-045459","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2023-12-19T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Semper Paratus shareholders approve extension to Sep 2024; $9.7M redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved extension of deadline to September 15, 2024 via one 3-month and six 1-month extensions.","880,873 Class A shares redeemed at ~$11.02/share for aggregate ~$9.7 million.","Trust account balance after redemptions and $67,500 payment is ~$16.5 million.","First extension to March 15, 2024 triggered by $67,500 deposit into trust.","Amendment to charter filed with Cayman Registrar to allow the extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267775,"accession_number":"0001493152-23-045201","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"SPAC Semper Paratus extends deadline to Sept 2024; $9.7M redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Extension Amendment allowing up to 9-month extension to Sept 15, 2024.","Holders of 880,873 Class A shares redeemed at ~$11.02 each, aggregate ~$9.7M.","Trust account balance after redemptions and extension deposit is ~$16.5M.","Sponsor SSVK Associates deposited $67,500 for the first three-month extension.","Extension provides additional time to complete an initial business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267774,"accession_number":"0001493152-23-041775","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Semper Paratus furnishes investor presentation for proposed Tevogen Bio merger","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation provides additional detail on June 28, 2023 merger agreement between SPAC and Tevogen Bio.","Transaction involves exchange of all Tevogen Bio capital stock for Semper Paratus Class A shares.","Closing conditions include shareholder approval, regulatory clearances, and minimum cash requirements.","No new financial projections or material updates disclosed in this filing beyond the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285003,"accession_number":"0001493152-23-034750","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Semper Paratus regains Nasdaq MVLS compliance effective Sept 28, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq letter Sept 28, 2023 confirming regained compliance with MVLS Rule (minimum $50M market value).","Non-compliance notice received April 7, 2023; initial cure period ran to Oct 2, 2023.","MVLS exceeded $50M for ten consecutive business days from Sept 14 to Sept 27, 2023.","Compliance regained; delisting risk from Nasdaq Global Market is removed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285002,"accession_number":"0001493152-23-032672","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Semper Paratus files S-4 for merger with Tevogen Bio; expects close near end of 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Filed Registration Statement on Form S-4 with SEC for proposed business combination with Tevogen Bio.","Combined company to be named Tevogen Bio Holdings Inc., expected to trade on NYSE American as TVGN/TVGNW.","Transaction approved by both boards; closing subject to SEC review, shareholder approval, and other conditions.","Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies in virology, oncology, neurology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304824,"accession_number":"0001493152-23-022852","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Semper Paratus Acquisition Corp. enters definitive merger with Tevogen Bio at $1.2B enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration: $1.2B in Semper Paratus Class A common stock; plus up to 20M earnout shares at price targets of $15, $17.50, $20.","Post-closing board: 7 directors, 6 designated by Tevogen Bio; CEO and CFO of Tevogen to continue in same roles.","Closing conditions: minimum $25M cash at close, shareholder approvals, SEC registration, and $5M net tangible assets.","Outside date: December 5, 2023; no termination fees; equity line of credit $35M-$60M possible but not required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304823,"accession_number":"0001493152-23-020433","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Semper Paratus Acquisition Corp. completes sponsor change; entire board and officers replaced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New Sponsor SSVK Associates purchased 7,988,889 Class A shares and 1,000,000 private placement units for $1.00.","All prior directors (Richard Peretz, Hooman Yazhari, Paul Jebely, Brad Stewart, Parizad Parchi) and officers resigned.","New directors appointed: Michael Peterson, Donald Fell, Avinaesh Wadhwani, Scott Sussman, and Surendra Ajjarapu.","Surendra Ajjarapu named CEO and Chairman; Francis Knuettel II named CFO.","No known disagreements with resigning directors on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304822,"accession_number":"0001104659-23-057818","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"SPAC Semper Paratus enters subscription and purchase agreements; cures Nasdaq delinquency","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Subscription Agreement with Polar Multi-Strategy Master Fund for $151k capital; SPAC will issue 151k Class A shares at de-SPAC close.","Purchase Agreement with SSVK Associates for $1: acquires 7,988,889 Class A shares and 1M private placement units; SSVK assumes SPAC obligations.","SSVK may replace directors/officers; deal conditions include board approval, underwriter consent, filing of Q1 2023 10-Q.","Nasdaq delisting risk cured after paying $151k fee; company now compliant and securities continue trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304821,"accession_number":"0001104659-23-043135","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Semper Paratus gets Nasdaq deficiency notice for MVLS below $50M","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Nasdaq notified Semper Paratus on April 4, 2023, that its MVLS fell below $50M, violating Listing Rule 5450(b)(2)(A).","The company has 180 calendar days, until October 2, 2023, to regain compliance by closing at $50M+ for 10 consecutive business days.","If not cured by that date, Nasdaq will issue a delisting notice; the company may appeal or seek transfer to the Nasdaq Capital Market.","The deficiency notice is not an immediate delisting and has no current effect on trading of LGSTU, LGST, or LGSTW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324359,"accession_number":"0001104659-23-038333","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Semper Paratus receives Nasdaq delisting notice for unpaid fees of $151,000","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received March 23, 2023 for failure to pay $151,000 in Nasdaq listing fees.","Trading of LGST, LGSTU, LGSTW to be suspended April 3, 2023 unless appeal is filed.","Company intends to pay outstanding balance and may appeal to a Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324358,"accession_number":"0001104659-23-017639","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Semper Paratus extends BC deadline to Dec 2023; $332M redeemed, trust reduced to $25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved charter amendment extending business combination deadline from Feb 8, 2023 to Dec 15, 2023.","Holders of 32,116,947 public shares elected redemption, receiving ~$332M ($10.34/share) from trust.","Post-redemption, trust account balance is ~$25M with only 2,383,053 public shares outstanding.","Class B shareholders converted all 11,983,333 Class B shares to Class A shares on a 1-for-1 basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324357,"accession_number":"0001104659-23-008577","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Semper Paratus initial shareholders convert all Class B shares to Class A","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11,983,333 Class B Founder Shares converted to Class A shares on a one-for-one basis.","After conversion, 47,933,333 Class A shares outstanding; no Class B shares remain.","Converted shares retain transfer restrictions, voting agreement, and trust waiver from Letter Agreement.","Conversion does not change voting power at the February 3, 2023 extraordinary general meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324356,"accession_number":"0001104659-23-006954","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Semper Paratus corrects trust account amount in proxy; per-share value $10.34 as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects typographical error: trust account per-share value is $10.34 as of Dec 31, 2022, up from $10.20 as of Sep 30, 2022.","Trust account balance approximately $256.35686 million as of record date Dec 31, 2022; prior filings had outdated figures.","EGM for extension vote remains scheduled for Feb 3, 2023; no change to business combination timeline.","If extension fails, liquidation yields $10.34 per share; warrants expire worthless."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377828,"accession_number":"0001104659-22-046527","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Philippe Kurzweil resigns; President Jeff Rogers appointed CFO and Secretary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philippe J. Kurzweil resigned as CFO and Secretary, effective April 13, 2022.","Jeff Rogers appointed CFO and Secretary, effective same day; he continues as President.","Rogers has served as President since November 2021; biography incorporated by reference from Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415149,"accession_number":"0001104659-21-154730","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2021-12-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Semper Paratus Acquisition Corp announces separate trading of Class A shares and warrants starting Jan 3, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 34,500,000 IPO units may elect to separate into Class A ordinary shares and warrants effective Jan 3, 2022.","Separated shares trade under LGST, warrants under LGSTW; units continue under LGSTU on Nasdaq.","No fractional warrants issued; only whole warrants will trade upon separation.","Holders must contact transfer agent Continental Stock Transfer & Trust to separate units.","Cantor Fitzgerald & Co. acted as sole book-running manager; registration declared effective Nov 3, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415148,"accession_number":"0001104659-21-139381","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Semper Paratus Acquisition Corporation closes IPO and private placement, raises $359.5M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 34.5M units at $10/unit raised $345M gross; private placement of 1.45M units raised $14.5M.","Total $351.9M deposited in trust account (Continental Stock Transfer & Trust Company as trustee).","SPAC must complete initial business combination by February 8, 2023 (15 months from IPO).","Audited balance sheet shows $352.9M total assets, $351.9M temporary equity for redeemable Class A shares.","Marcum LLP issued unqualified audit opinion; company has no operations yet and will search for target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415147,"accession_number":"0001104659-21-135566","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Semper Paratus closes $345M SPAC IPO; $351.9M placed in trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO of 34.5M units at $10.00 each, including full exercise of 4.5M-unit over-allotment.","Gross IPO proceeds of $345M; private placement of 1.3M units to sponsor ($13M) and 150K units to Cantor ($1.5M).","Trust account funded with $351.9M from IPO proceeds and private placements; 15-month deadline for business combination.","Brad Stewart and Parizad Olver Parchi appointed to board; audit and compensation committees formed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}